[Axol Biosciences] Tamoxifen-Resistant MCF7 Breast Cancer Cells (MCF7/TAMR-4)
Product Code: ax4011
Product Specification
| Donor gender | Female |
| Donor age at sampling | 69 yrs |
| Genetic modification | None |
| Size | 1 million cells |
| Growth properties | Adherent |
| Disease information | Malignant adenocarcinoma derived from pleural effusion |
| General notes | Expresses the estrogen receptor (ER); resistant to tamoxifen at 1 μM |
| Shipping conditions | Dry ice |
| Storage conditions | vapour phase nitrogen |
| Usage notes | Culture in DMEM/F12 medium (no phenol red) supplemented with 1% fetal bovine serum + 2.5 mM GlutaMAX + 6 ng/mL insulin. Addition of 1 μM tamoxifen is required to maintain a high level of resistance |
| Condition of sale | The end user is not permitted to transfer or re-freeze the cells |
MCF7/TAMR-4 and MCF7/TAMR-8 are tamoxifen-resistant MCF7 breast cancer cell lines. The parental MCF7/S0.5 line was treated with 1 μM tamoxifen for 28 days which killed the majority of the cells. The surviving cells were clonally expanded as sublines in the absence of tamoxifen for 19 passages and were then treated continuously with 1 μM tamoxifen. The resistant cells continued to proliferate and approached a growth rate that was comparable to the parental MCF7/S0.5 line.
Condition of sale: the end user is not permitted to transfer or re-freeze the cells.